Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) have been assigned an average rating of “Hold” from the eight research firms that are currently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company.
Several analysts have recently commented on the company. Redburn Atlantic lowered Bayer Aktiengesellschaft from an “overweight” rating to a “neutral” rating in a report on Monday, September 25th. Wolfe Research started coverage on shares of Bayer Aktiengesellschaft in a report on Wednesday, July 19th. They set an “outperform” rating on the stock. Deutsche Bank Aktiengesellschaft lowered Bayer Aktiengesellschaft from a “buy” rating to a “hold” rating in a report on Tuesday. HSBC raised Bayer Aktiengesellschaft from a “reduce” rating to a “hold” rating in a report on Tuesday, October 10th. They noted that the move was a valuation call. Finally, Berenberg Bank cut shares of Bayer Aktiengesellschaft from a “buy” rating to a “hold” rating in a research note on Wednesday, August 16th.
Bayer Aktiengesellschaft Stock Up 1.0 %
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last announced its quarterly earnings results on Wednesday, November 8th. The company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.10). Bayer Aktiengesellschaft had a negative net margin of 7.98% and a positive return on equity of 14.76%. The firm had revenue of $11.26 billion during the quarter, compared to analysts’ expectations of $12.62 billion. On average, equities analysts expect that Bayer Aktiengesellschaft will post 1.69 EPS for the current year.
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
- Five stocks we like better than Bayer Aktiengesellschaft
- The Significance of Brokerage Rankings in Stock Selection
- 3 value stocks you shouldn’t let go of this quarter
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 5 must-have next-gen technologies that institutions are buying
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 3 intriguing late-week earnings plays for short-term traders
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.